ISPOR - Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Full Text

Economic Evaluation of Nivolumab (NIVO) Plus Ipilimumab (IPI) Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada

Abstract

Authors

P Quon Y Xiao S Sorensen M Schultz AA Tahami Monfared

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now